Sign In
NewsRadar

Pharmalink

Pharmalink is a specialty pharma company that develops pharmaceutical products in fields of unmet medical need. It has adopted a reformulation/repurposing strategy. The company currently has three clinical phase development projects, Nefecon, Xepol and Busulipo, mature for out-licensing to commercial partners and also seeks to refill its development pipeline by inlicensing.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
P.O Box 5385
Stockholm 102 49
Sweden
+46 (0)8 505 66 312
+46 (0)8 611 3303
http://www.pharmalink.se
Johan Häggblad
+46 70 668 0644

Company Facts
Founded:Dec 1991
Founders:Bengt Julander, Mikael Bender
CEO:Johan Häggblad
CTO or technical lead:
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:Growth
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,673
Tech investments
From our Online Data Service
17,217
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.